The effect of apolipoprotein mimetic peptides in inflammatory disorders other than atherosclerosis

Trends Cardiovasc Med. 2008 Feb;18(2):61-6. doi: 10.1016/j.tcm.2007.12.006.

Abstract

Apolipoprotein mimetic peptides have been shown to dramatically reduce atherosclerosis in animal models. Atherosclerosis is an example of an inflammatory disorder. Published studies of apolipoprotein mimetic peptides in models of inflammatory disorders other than atherosclerosis suggest that they may have efficacy in a wide range of inflammatory conditions.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Apolipoprotein A-I / physiology
  • Apolipoprotein A-I / therapeutic use*
  • Apolipoproteins / physiology*
  • Apolipoproteins / therapeutic use
  • Atherosclerosis / physiopathology*
  • Diabetes Mellitus, Experimental / physiopathology
  • Humans
  • Infections
  • Inflammation / physiopathology*
  • Molecular Mimicry
  • Peptides / physiology
  • Vascular Diseases / physiopathology
  • Vascular Diseases / therapy

Substances

  • Apolipoprotein A-I
  • Apolipoproteins
  • D-4F peptide
  • Peptides